Clinical trial NCT04089163: A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)
Official title: Toca 8: A Multicenter, Open-Label, Phase 1 Study to Evaluate the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Bladder Cancer
Keywords: non-muscle invasive bladder cancer
bladder cancer
high grade non-muscle invasive bladder cancer
HG NMIBC
NMIBC
high grade NMIBC
Lead sponsor: Tocagen Inc.
Sponsor class: INDUSTRY
First posted: 2019-09-13
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Intervention model: SEQUENTIAL
Intervention model description: 3+3 dose escalation design with expansion at recommended Phase 2 dose.
Primary purpose: TREATMENT

Brief summary: This is a Phase 1, multicenter, open-label study of intravesical Toca 511 followed by oral Toca FC in patients with high grade (HG) non-muscle invasive bladder cancer (NMIBC), with cohort expansion at the recommended Phase 2 dose. Patients with recurrent HG NMIBC who are undergoing planned transurethral resection of bladder tumor (TURBT) will be enrolled into the study, subject to meeting all entry criteria.


Eligibility criteria: Inclusion Criteria:

* Provide written informed consent to participate
* At least 18 years of age
* Recurrent HG NMIBC, with HG tumor on previous histopathology
* Undergoing planned TURBT and biopsy of CIS suspicious areas
* No imaging findings consistent with T2 or greater disease, hydronephrosis, extravesical disease, nodal involvement, metastases, or other malignancies.
* Able and willing to wait at least 2 weeks following intravesical administration of Toca 511 to undergo TURBT
* If patient is a candidate for standard of care (SOC) intravesical therapy, able and willing to wait at least 2 weeks post-TURBT for initiation of such treatment
* Patient is able to be catheterized and is anticipated to be able to retain Toca 511 for approximately 2 hours
* Estimated life expectancy of at least 12 months
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
* Patient has adequate organ function, as indicated by the following laboratory values

  * Complete blood count: hemoglobin ≥ 10 g/dL, platelet count ≥ 100,000/mm\^3, absolute neutrophil count ≥ 1,500/ mm\^3, absolute lymphocyte count ≥ 500/ mm\^3
  * Liver: total bilirubin ≤ 1.5 × the upper limit of normal (ULN; unless known Gilbert's syndrome); alanine aminotransferase ≤ 2.5 × ULN
  * Kidney: estimated glomerular filtration rate (GFR: Cockcroft-Gault) ≥ 50 mL/min
* Women of childbearing potential (defined as not postmenopausal \[ie, ≥ 12 months of non-therapy-induced amenorrhea\] or not surgically sterile) must have a negative serum pregnancy test within 7 days prior to administration of Toca 511, and be willing to use an effective means of contraception in addition to barrier methods (condoms) for the duration of the study.
* Patient and partner are willing to use condoms for 12 months after receiving Toca 511 and/or 30 days after the last dose of Toca FC, and/or until there is no evidence of the virus in his/her blood or urine, whichever is longer.

Exclusion Criteria:

* History of urothelial cancer in the upper tract or urethra; muscle invasive bladder cancer; or metastatic bladder cancer
* History of bladder tumors other than urothelial carcinoma (ie, neuroendocrine, adenocarcinoma, or squamous cell carcinoma)
* Treatment with intravesical agents within 28 days prior to Toca 511 administration
* TURBT within 12 weeks prior to planned Toca 511 administration
* History of pelvic radiation
* Bladder tumor located within a bladder diverticulum
* Genitourinary procedures (eg, prostate surgery; treatment of ureteral stones or moderate to extensive urethral stricture disease) prior to, during, or planned within the 4 weeks following TURBT, other than procedures for treatment of bladder tumors
* Severe lower urinary tract dysfunction clinically manifest as poor capacity, disabling incontinence, chronic catheter use, or chronic infections or stones
* Presence of suprapubic catheter
* History of other malignancy, unless the patient has been disease-free for at least 5 years. Adequately treated basal cell carcinoma or squamous cell skin cancer is acceptable regardless of time, as well as cervical carcinoma in situ or localized prostate carcinoma, after curative treatment. (Note: Men with very low or low risk prostate cancer on active surveillance are acceptable candidates for this study.)
* Active infection requiring antibiotic, antifungal, or antiviral therapy within 2 weeks prior to administration of Toca 511
* Investigational treatment within 2 weeks or immunotherapy or antibody therapy within 28 days prior to Toca 511 administration, and/or has not recovered from toxicities associated with such treatment
* Chronic treatment with autoimmune medications
* Human immunodeficiency virus (HIV) seropositive
* Pregnant or breast feeding
* Bleeding diathesis, or required to take anticoagulants or antiplatelet agents, including nonsteroidal anti-inflammatory drugs, that cannot be stopped for surgery
* Severe pulmonary, cardiac, or other systemic disease, specifically:

  * New York Heart Association \> Class II congestive heart failure that is not controlled on standard therapy within 6 months prior to Toca 511 administration
  * Uncontrolled or significant cardiovascular disease, clinically significant ventricular arrhythmia (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes), clinically significant pulmonary disease (such as ≥ Grade 2 dyspnea)
  * Any other serious medical, social, or psychological condition that, based on Investigator assessment, may affect the patient's compliance or place the patient at an increased risk of potential treatment complications
* History of allergy or intolerance to flucytosine
* Presence of a condition that would prevent the patient from being able to swallow Toca FC tablets

Primary outcomes:
measure: Dose-limiting toxicities
timeFrame: 5 weeks
Secondary outcomes:
measure: Differences in viral transduction of Toca 511 at each dose level, based on quantitation of viral RNA and DNA in tumor
timeFrame: 3 weeks (+/- 1 week)
measure: Clearance of viral RNA in plasma and urine, based on real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR), and of viral DNA in whole blood and urine, based on quantitative PCR (qPCR)
timeFrame: 1 week for plasma, 4 weeks for urine
Other outcomes:
measure: Changes from baseline in immune activity in tumor, peripheral blood, and urine
timeFrame: 21 weeks
measure: Complete response rate at 6 and 12 months in patients with carcinoma in situ (CIS)
timeFrame: Proportion of patients with CIS with complete response at 6 and 12 months
measure: High-grade recurrence-free survival
timeFrame: Event free survival overall and at 6 and 12 months
measure: Incidence of cystectomy
timeFrame: The proportion of patients who undergo cystectomy
measure: Incidence of disease progression at 6 and 12 months
timeFrame: The proportion of patients with disease progression at 6 and 12 months
Locations:
Study officials:
References: